Solving the $100,000 Cancer Drug Problem
Harvard Business Review
MAY 2, 2013
Last week over 100 leading cancer specialists signed their names to an op-ed in Blood , the journal of the American Society of Hematology, which lambasted the prices of cancer drugs that often exceed $100,000 annually. While pharma companies spend billions on research, the actual cost of manufacturing a treatment (such as a pill) is minimal.
8 
Let's personalize your content